Zoledronic acid improves bone mineral density, reduces bone turnover and improves skeletal architecture over 2 years of treatment in children with secondary osteoporosis
Research output: Contribution to journal › Journal article › Research › peer-review
There are limited data on the use of bisphosphonate therapy for secondary osteoporoses in childhood, and no previous reports of the use of zoledronic acid in this group. We report 20 children with a variety of underlying primary diagnoses with associated secondary osteoporosis, who were treated with 3 monthly zoledronic acid for 2 years (annualised dose 0.1mg/kg/year). There was a significant improvement in lumbar spine (by 1.88 SD±1.24 over first 12 months, p
| Original language | English |
|---|---|
| Journal | Bone |
| Volume | 49 |
| Issue number | 5 |
| Pages (from-to) | 939-43 |
| Number of pages | 5 |
| ISSN | 8756-3282 |
| DOIs | |
| Publication status | Published - 2011 |
ID: 40165515